Fitaro 2.4 mg is an injectable medication containing Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for weight management and as an adjunct therapy for patients with obesity or overweight with at least one weight-related comorbidity. Semaglutide mimics the action of the naturally occurring GLP-1 hormone, which regulates appetite, food intake, and glucose metabolism.

By activating GLP-1 receptors in the pancreas and brain, Semaglutide:

• Enhances insulin secretion in response to elevated blood glucose

• Suppresses glucagon release

• Delays gastric emptying, promoting satiety

• Reduces caloric intake, supporting significant weight reduction

Fitaro 2.4 mg is intended for long-term use, in combination with a reduced-calorie diet and increased physical activity, to achieve sustained weight loss and improve metabolic health.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

GLP-1 Receptor Agonists

Pharmacology

Semaglutide is a long-acting GLP-1 analog with modifications that prolong its half-life, allowing once-weekly subcutaneous administration. It binds to GLP-1 receptors on pancreatic β-cells, increasing glucose-dependent insulin secretion, and inhibiting glucagon release from α-cells. Additionally, it acts on appetite-regulating centers in the hypothalamus to reduce hunger and food intake.

Clinical studies have shown that Semaglutide leads to significant and sustained reductions in body weight, body mass index (BMI), and waist circumference, with beneficial effects on blood pressure and lipid profiles.

Indications

Fitaro 2.4 mg Injection is indicated for:

• Management of obesity (BMI ≥30 kg/m²)

• Management of overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia

• Adjunct to dietary and lifestyle interventions for long-term weight management

Dosage and Administration

• Adults: Administer 2.4 mg subcutaneously once weekly at any time of day, with or without meals

• Start with a lower dose and gradually escalate to minimize gastrointestinal side effects: typically beginning at 0.25 mg weekly and increasing every 4 weeks to reach the target 2.4 mg

• Inject into the abdomen, thigh, or upper arm

• Consistency in weekly dosing is recommended to maintain efficacy

Note: Dosage adjustment is not required for mild or moderate renal impairment, but caution is advised in severe renal or hepatic impairment.

Drug Interactions

• Oral medications: Semaglutide may delay gastric emptying, potentially affecting absorption of oral drugs; monitor when co-administering critical medications such as oral contraceptives or antidiabetic agents.

• Other glucose-lowering drugs: Risk of hypoglycemia increases when combined with insulin or sulfonylureas.

Contraindications

• Known hypersensitivity to Semaglutide or any component of the injection

• History of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Side Effects

Common adverse effects include:

• Nausea, vomiting, diarrhea, constipation, and abdominal pain

• Decreased appetite

• Injection site reactions

• Rare: pancreatitis, gallbladder disease, hypoglycemia when used with other antidiabetic agents

Precautions and Warnings

• Monitor blood glucose in diabetic patients

• Use caution in patients with a history of pancreatitis or severe gastrointestinal disease

• Regular monitoring of renal and liver function is advised during long-term therapy

Pregnancy and Lactation

• Pregnancy: Not recommended. The effects on human pregnancy are unknown.

• Lactation: Use caution; it is unknown whether Semaglutide is excreted in human milk.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Conditions

• Store unopened pens in a refrigerator (2–8°C)

• Do not freeze; protect from light

• Once opened, the pen may be kept at room temperature (<30°C) for up to 56 days